1.71 -0.1 (-5.52%) | 02-12 19:26 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 5.88 | 1-year : | 8.4 |
Resists | First : | 5.04 | Second : | 7.19 |
Pivot price | 2.17 ![]() |
|||
Supports | First : | 1.54 | Second : | 1.28 |
MAs | MA(5) : | 1.84 ![]() |
MA(20) : | 2.28 ![]() |
MA(100) : | 1.72 ![]() |
MA(250) : | 2.67 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 1.4 | D(3) : | 1.4 ![]() |
RSI | RSI(14): 40.1 ![]() |
|||
52-week | High : | 7.19 | Low : | 1.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SLRX ] has closed above bottom band by 9.2%. Bollinger Bands are 53.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 1.81 - 1.82 | 1.82 - 1.84 |
Low: | 1.68 - 1.69 | 1.69 - 1.71 |
Close: | 1.69 - 1.71 | 1.71 - 1.73 |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Mon, 03 Feb 2025
Salarius Pharmaceuticals Announces Patient Enrollment to - GlobeNewswire
Mon, 03 Feb 2025
Breakthrough Cancer Treatment Shows Triple Survival Time: Trial Back on Track - StockTitan
Mon, 13 Jan 2025
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
Mon, 13 Jan 2025
Salarius Pharmaceuticals Merges with Decoy Therapeutics - TipRanks
Mon, 13 Jan 2025
Salarius Pharma Merges with AI Drug Designer Decoy Therapeutics, Plans Pan-Coronavirus Drug - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 2 (M) |
Shares Float | 1 (M) |
Held by Insiders | 2.5 (%) |
Held by Institutions | 0.3 (%) |
Shares Short | 65 (K) |
Shares Short P.Month | 15 (K) |
EPS | -5.14 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 10.73 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -54 % |
Return on Equity (ttm) | -119.9 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -4.26 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -8 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | -0.34 |
PEG Ratio | 0 |
Price to Book value | 0.15 |
Price to Sales | 0 |
Price to Cash Flow | -0.36 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |